EtiraRx is a series a startup based in United States. 2 investors tracked.
EtiraRx is a company headquartered in the United States. Its most recent tracked round is Series A. Brouky records 2 investors associated with the company.
EtiraRx is a clinical-stage biopharmaceutical company developing a new class of cancer therapeutics that target the PI3K/AKT/mTOR pathway to induce cancer-specific cell death.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.